SLAMF7 and Miyoshi myopathy: This mAb can facilitate NK cell-mediated ADCC of MM cells through Fc-dependent interactions with FcγRIIIA (CD16), it can promote macrophage-mediated ADCP of MM cells through Fc-dependent interactions with Fcγ receptor, and it can also directly bind to SLAMF7 on NK cells and activate them [140,141].